Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semglee vs Lantus in T2DM (INSTRIDE 2)
NCT02227875Phase 3Completed
- Sponsor
- Mylan
- Start
- Aug 2014
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Mylan. Primary endpoint: Change in Glycosylated Hemoglobin at 24 weeks. Started Aug 2014; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02227875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227875.